First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis

In chronic kidney disease both renal insufficiency and chronic inflammation trigger elevated hepcidin levels, which impairs iron uptake, availability. and erythropoiesis. Here we report the two first-in-human phase 1 trials of PRS-080#22, a novel, rationally engineered Anticalin protein that targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Renders, Lutz, Budde, Klemens, Rosenberger, Christian, van Swelm, Rachel, Swinkels, Dorine, Dellanna, Frank, Feuerer, Werner, Wen, Ming, Erley, Christiane, Bader, Birgit, Sommerer, Claudia, Schaier, Matthias, Meurer, Karoline, Matis, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436791/
https://www.ncbi.nlm.nih.gov/pubmed/30917125
http://dx.doi.org/10.1371/journal.pone.0212023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436791/
https://www.ncbi.nlm.nih.gov/pubmed/30917125
http://dx.doi.org/10.1371/journal.pone.0212023

Ejemplares similares